Prestige BioPharma announced this week that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for a proposed trastuzumab biosimilar, HD201. Prestige hopes to eventually sell the product under the name Tuznue.
Prestige BioPharma announced this week that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for a proposed trastuzumab biosimilar, HD201, referencing Herceptin. Prestige hopes to eventually sell the product under the name Tuznue.
Lisa S. Park, PhD, chief executive officer of Prestige, said in a statement announcing the application, “We are very pleased that EMA has initiated the review of the HD201 Marketing Authorization Application. It is a major step in our endeavor to become a global player focusing on biosimilars and innovative biologics. Our development approach has proven to be highly efficient with regard to trial performance, demonstrating exceptional similarity, and dossier filing.”
Data published ahead of the 2019 of the American Society of Clinical Oncology meeting highlight the development process for the proposed biosimilar; first, say researchers, analytical comparability in terms of physiochemical and biological properties was assessed for the proposed biosimilar and the EU- and US-licensed reference Herceptin.1
Next, a single-dose phase 1 trial assessed the pharmacokinetic (PK) equivalence between the biosimilar and the EU reference in healthy volunteers. This study showed, say the investigators, that HD201 is safe and well tolerated, and has comparable PK to the EU reference after a single-dose administration.
Following the phase 1 study, a randomized, double-blind, parallel group, multicenter phase 3 study was conducted in comparison with the EU-licensed reference in 500 patients with HER2-positive early breast cancer. According to the investigators, an analysis of a substudy from this phase 3 trial showed comparable results for the biosimilar and the EU reference.
Prestige is also preparing its hopeful launch of the biosimilar; in late 2018, Prestige announced that it had entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets. Earlier, Prestige announced a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
Reference
1. Hii J, Pivot X, Park LS, et al. HD201: analytical biocomparability and clinical trial progression of trastuzumab [published online May 26, 2019]. J Clin Oncol. doi: 10.1200/JCO.2019.37.15_suppl.e12505.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.